SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery

作者：Bianca M. Dijkstra, Arash Motekallemi, Wilfred F.A. den Dunnen, Hanne‐Rinck Jeltema, Gooitzen M. van Dam, Frank A.E. Kruyt, Rob J. M. Groen · 发表于：Acta Neurochirurgica · 年份：2018 · DOI：10.1007/s00701-018-3575-z · 被引用次数：32 · 研究领域：Meningioma and schwannoma management、Nanoplatforms for cancer theranostics、Neurofibromatosis and Schwannoma Cases

BACKGROUND: Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative techniques have been tried to improve surgical resection, including intraoperative fluorescence guided imaging; however, no meningioma-specific (fluorescent) targeting has been developed yet. Here, we aimed to identify the most promising biomarkers for targeted intra-operative fluorescence guided meningioma surgery. METHODS: One hundred forty-eight meningioma specimens representing all meningioma grades were analysed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet-derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on TArget Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumour material. RESULTS: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 51.4% strong/diffuse, 30.4% moderate/diffuse and only 18.2% focal/weak staining patterns. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. TASC...